Pipeline Strategy: Balancing Science, Feasibility, and ROI in Clinical Development Decisions
What does it take to make confident, cross-functional pipeline decisions that drive approval speed and sustainable value for companies in today’s clinical research landscape?
Moderated by Emily Roberts-Thomson, Development Operations Leader
Featuring:
• Raj Patel, Chief Operating Officer, ReacX Pharmaceuticals
• Nikhil Dube, Lifecycle Management Strategy Lead, Biogen
• Mukhtar Ahmed, Director, Project and Portfolio Strategy, Greenstone Biosciences
Recorded live at COG Bay Area, this panel brings together senior voices from leading biotech and pharma organizations to tackle the realities of pipeline prioritization and clinical operations best practices. Moderated by Emily Roberts-Thomson, the discussion centers on actionable frameworks and leadership judgment required for effective clinical trial outsourcing, CRO selection, and cross-functional portfolio management.
The panelists break down how organizations decide which programs to advance, weighing scientific potential against development feasibility, market factors, risk, and resource constraints. They candidly explore trade-offs inherent to outsourcing strategies, clinical study optimization, and how changes in ROI, timelines, or operational setbacks impact pipeline decisions.
Essential listening for clinical operations leaders, outsourcing specialists, and study owners, the episode delivers practical insights on moving from scientific conviction to commercial success—and ensuring alignment across sponsors, CRO partners, and governance bodies in a rapidly shifting environment for clinical trial outsourcing.
Key topics include:
- Balancing science, feasibility, and business drivers in pipeline advancement decisions
- Managing cross-functional alignment across R&D, clinical operations, and commercial teams for better governance
- The critical role of financing, investor expectations, and real-world feasibility in CRO selection and vendor management
Key Moments
00:03:20 – Emily Roberts-Thomson frames the multifactor decision: “It’s never just about how good the science is. It’s about feasibility, market dynamics, and resource allocation.”
00:04:00 – Raj Patel outlines a practical pipeline selection matrix: fastest to approval, least cost, minimal risk—plus the real-world influence of boardroom priorities and investor interests.
00:05:00 – Nikhil Dube shares a three-pronged approach: scientific value, clinical development feasibility, and commercial opportunity—all critical for clinical study optimization and vendor selection frameworks.
00:06:37 – Mukhtar Ahmed describes a hybrid model leveraging academic depth and operational agility, focusing on robust human data and milestone-driven inflection points for outsourcing viability.
00:08:02 – Panel debate: How companies trade off first-in-class scientific programs against downstream commercial opportunity when making outsourcing or CRO selection decisions.
00:13:28 – Emily Roberts-Thomson and Raj Patel candidly discuss the reality of reprioritizing clinical studies based on changing business needs and operational feasibility—impacting CRO and vendor engagement.
00:14:29 – Achieving cross-functional consensus: Lessons from balancing scientific advocacy, operational feasibility, and business priorities in pipeline governance.
00:17:05 – Raj Patel on how investors and shifting market landscapes dictate which programs move forward—and how funding realities drive clinical outsourcing strategies.
00:19:13 – Nikhil Dube unpacks how project leads in large pharma orchestrate collaboration across research, development, commercial, and outsourcing teams for better governance and vendor alignment.
00:22:56 – Mukhtar Ahmed on the importance of transparent, all-hands communication and real-world feasibility checks with KOLs and clinical trial site experts when planning outsourcing for early-phase studies.
Top 3 Takeaways
- Balance Science and Feasibility with Business Realities
- Even the most promising science requires practical validation against operational costs, study feasibility, and commercialization potential—crucial for smart clinical trial outsourcing and CRO selection.
- Cross-Functional Collaboration Drives Success
- Early, transparent input from R&D, clinical operations, and commercial leaders creates alignment and sets up clinical operations best practices for study optimization and outsourcing partnerships.
- Investor and Market Pressures Shape Pipeline and Outsourcing Choices
- Shifts in funding, risk tolerance, and evolving market needs can upend study priorities—requiring agile, milestone-based approaches and robust clinical outsourcing governance.
Links & Resources
Clinical Outsourcing Group (COG) Events – https://thepbcgroup.com/cog-events
Biogen – https://www.biogen.com
Greenstone Biosciences – https://greenstonebio.com
ReacX Pharmaceuticals – https://reacxpharma.com/
National Institute on Drug Abuse – https://nida.nih.gov
Quotes
“It’s never just about how good the science is. It’s about balancing the potential with feasibility, market dynamics, and resource allocation.” – Emily Roberts-Thomson
“You have to make some tough decisions… which product will give you the fastest approval, for the least money, with minimal risk.” – Raj Patel
“Every company uses the same three pillars: scientific conviction, development feasibility, and commercial opportunity.” – Nikhil Dube
“If you don’t have the funds, you might have the best science, but you’re not going to get anywhere.” – Raj Patel
“We try to always come back to how quickly we can get human-relevant data, early on. That’s what drives both scientific confidence and investor capital.” – Mukhtar Ahmed
“Cross-functional alignment is near and dear… silos have no place in small biotech.” – Mukhtar Ahmed
-----------
Further content and agendas: hhttps://thepbcgroup.com
Copyright 2026 The PBC Group
